SNIPR Biome has said its CRISPR therapeutic targeting a problem bacterial pathogen has shown proof-of-concept in a phase 1 trial, raising hopes of a new way to treat resis
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh